Mouse Hepatitis Virus

Overview and Taxonomy of Mouse Hepatitis Virus

Mouse hepatitis virus (MHV) is a prototypic member of the family Coronaviridae, genus Betacoronavirus, and represents the eponymous species Murine coronavirus [1]. As a murine coronavirus, MHV has served as an indispensable small-animal model for understanding the biology, pathogenesis, and host interactions of coronaviruses, particularly in the context of hepatotropic and neurotropic disease. Its study has illuminated fundamental principles of coronavirus replication, receptor usage, and immune evasion that are broadly applicable to human coronaviruses, including severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and SARS-CoV-2. The World Health Organization (WHO) and the World Organisation for Animal Health (OIE) recognize the critical importance of coronaviruses as emerging and re-emerging pathogens, and MHV remains a cornerstone model system for investigating these agents.

Taxonomic Position and Historical Context

MHV is classified within the order Nidovirales, family Coronaviridae, subfamily Orthocoronavirinae, genus Betacoronavirus, and species Murine coronavirus [1]. Historically, MHV was one of the first coronaviruses to be isolated and characterized, with early studies in the 1960s and 1970s establishing its basic virological properties. Initial electron microscopic investigations revealed the characteristic coronavirus morphology: pleomorphic, enveloped particles approximately 75 nm in diameter, bearing club-shaped surface projections (spikes) and containing a helical nucleocapsid [6]. The virion exhibits a dense core or nucleoid composed of the genomic RNA complexed with the nucleocapsid (N) protein, surrounded by a lipid bilayer derived from intracellular membranes [6].

The species Murine coronavirus encompasses a diverse group of viral strains that have been isolated from laboratory mouse colonies and wild rodent populations worldwide. These strains exhibit a spectrum of tissue tropisms, ranging from primarily hepatotropic (e.g., MHV-A59, MHV-3) to predominantly neurotropic (e.g., MHV-JHM, MHV-4), with significant variation in virulence [1, 2, 9]. This strain diversity has made MHV an exceptionally powerful tool for dissecting the genetic and molecular determinants of coronavirus pathogenesis, cell tropism, and host susceptibility.

Genomic Organization and Structural Features

The MHV genome is a single-stranded, positive-sense RNA molecule of approximately 31 kilobases, making it one of the largest known RNA viral genomes. The 5' end is capped, and the 3' end is polyadenylated, with the poly(A) tail being approximately 90 nucleotides in length, a feature essential for viral mRNA stability and translation [19]. The genomic RNA serves as the template for both replication and transcription, and it functions as an mRNA for the translation of the large replicase polyproteins (pp1a and pp1ab) from open reading frames (ORFs) 1a and 1b. Ribosomal frameshifting between these ORFs, mediated by a pseudoknot structure, allows the expression of the RNA-dependent RNA polymerase (RdRp) and other non-structural proteins (nsps) that form the replication-transcription complex (RTC) [11].

Downstream of the replicase gene, the MHV genome contains a set of structural and accessory protein genes arranged in a characteristic 3' co-terminal nested set structure. The structural proteins include the spike (S) glycoprotein, the envelope (E) protein, the membrane (M) glycoprotein (also referred to as E1), and the nucleocapsid (N) protein [5, 12, 13]. The S glycoprotein is a large, type I transmembrane protein that forms the prominent surface spikes and mediates receptor binding and membrane fusion. The M glycoprotein is the most abundant virion component, possessing a triple-spanning transmembrane domain and O-linked oligosaccharides that are critical for viral assembly and budding [16]. The N protein is a highly basic, phosphorylated protein that binds the genomic RNA to form the helical nucleocapsid; sequence analysis of the N gene across multiple MHV strains (A59, 3, S, 1, and JHM) has revealed a three-domain architecture with conserved N- and C-terminal domains connected by divergent spacer regions [18]. This structural conservation underscores the essential roles of the N protein in RNA packaging, replication, and modulation of host cell processes.

The replicase gene products, including the multi-domain nsp1, are of particular interest for pathogenesis. Nsp1 of MHV contains a relatively conserved LLRKxGxKG motif, and deletion of this region results in marked attenuation of the virus in vivo while preserving immunogenicity, highlighting the role of nsp1 in host-cell translational shutoff and innate immune evasion [3].

Strain Diversity, Receptors, and Host Susceptibility

The taxonomy of MHV is further complicated by the existence of multiple strains that differ in their pathogenicity, tissue tropism, and receptor usage. The primary cellular receptor for MHV is carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), a member of the CEA family of glycoproteins [4, 8]. CEACAM1 is expressed on hepatocytes, intestinal epithelial cells, and some leukocyte subsets, and its expression profile largely dictates the sites of MHV replication in vivo [8]. However, not all mouse strains are equally susceptible to MHV infection. Genetic studies have identified two major allelic forms of the CEACAM1 gene: Ceacam1a (susceptible allele) and Ceacam1b (resistant allele) [4]. Mice expressing the CEACAM1b isoform, such as SJL/J mice, are highly resistant to infection by most MHV strains due to reduced receptor function [4, 23]. This resistance can be overcome by using high doses of virus or by selecting for variant strains that can utilize CEACAM1b, but the genetic basis of resistance extends beyond receptor polymorphism alone. Other host factors, including genes on chromosome 7 that control macrophage permissiveness, contribute to the overall susceptibility phenotype [4, 20].

The interplay between viral strain and host genetics is elegantly illustrated by studies of MHV-3 infection in various inbred mouse strains. MHV-3 is highly hepatovirulent and causes fulminant hepatitis with high mortality in susceptible strains (e.g., C57BL/6, DBA/2) but induces only mild, transient disease in resistant strains (e.g., A/J) [7, 14, 17]. Resistance in A/J mice is not absolute; it is age-dependent and can be overcome by treatment with anti-interferon antibodies, indicating that type I interferon (IFN) responses are critical for control [17]. In contrast, susceptible C57BL/6 mice exhibit a delayed or insufficient IFN response, leading to unchecked viral replication and severe liver pathology.

Similarly, the neurotropic JHM strain (MHV-4) demonstrates pronounced strain-specific differences in disease outcome. BALB/c mice are highly susceptible to JHMV-induced encephalomyelitis, while SJL/J mice are resistant, with resistance mapping to a single autosomal gene that acts at the level of the neuron [9]. In resistant mice, neurons fail to support productive viral replication, despite apparently normal receptor expression [9]. This observation underscores that post-entry blocks, rather than receptor binding alone, are major determinants of cellular permissiveness.

Subgenomic mRNA Synthesis and the Nested Set Structure

A defining feature of coronavirus transcription, and one that is central to the taxonomy and evolution of MHV, is the production of a 3' co-terminal nested set of subgenomic mRNAs (sg mRNAs). Early biochemical studies in MHV-A59-infected Sac(-) cells identified seven virus-specific RNA species with molecular weights ranging from 5.6 × 10⁶ (genomic RNA) to 0.6 × 10⁶ (the smallest subgenomic RNA, mRNA 7) [12]. These sg mRNAs share identical 5' leader sequences and 3' terminal sequences but differ in their internal coding regions. Functional analyses in Xenopus laevis oocytes demonstrated that mRNA 7 encodes the N protein, mRNA 6 encodes the small envelope proteins (E and possibly others), and mRNA 3 encodes a high-molecular-weight glycoprotein (likely the S protein) [13].

The mechanism by which these sg mRNAs are generated involves a unique process of discontinuous transcription. During negative-strand synthesis, the viral RdRp pauses at transcription-regulating sequences (TRSs) located upstream of each structural and accessory gene. The nascent negative strand then undergoes a template-switching event, in which the 3' end of the nascent RNA base-pairs with the leader TRS at the 5' end of the genome, thereby generating a subgenomic negative-strand RNA that serves as the template for sg mRNA synthesis [21]. This discontinuous transcription model is supported by the detection of small leader-containing RNA intermediates in infected cells, which likely represent paused or prematurely terminated transcripts [21]. The high frequency of RNA recombination observed during MHV infection is thought to be a consequence of this non-processive polymerase activity, which can lead to template switching between co-infecting viral genomes [15, 21].

Defective Interfering Particles and Persistent Infection

Serial undiluted passage of MHV in cell culture leads to the accumulation of defective interfering (DI) particles, which contain extensively deleted genomes [10]. For MHV-JHM, DI particles arise after 6–8 serial undiluted passages and are characterized by a reduction in genomic RNA molecular weight from 5.4 × 10⁶ to 5.2 × 10⁶, with the loss of specific RNase T1-resistant oligonucleotides [10]. These DI particles interfere with the replication of standard virus and contribute to the establishment and maintenance of persistent infections both in vitro and in vivo. The generation of DI particles and the selection of viral variants with altered virulence are dynamic processes that underpin the ability of MHV to cause chronic, relapsing diseases such as chronic granulomatous hepatitis and demyelinating encephalomyelitis [14, 22].

Epidemiological Context and Regulatory Considerations

MHV is an endemic pathogen in laboratory mouse colonies worldwide and is considered a significant source of confounding variables in biomedical research. The OIE lists MHV as a listed pathogen for laboratory animal health monitoring, and stringent biosecurity measures are recommended to prevent its introduction and spread within research facilities. The World Health Organization (WHO) recognizes coronaviruses as a family of global health importance, and the insights gained from MHV research, particularly regarding receptor interactions, innate immune evasion, and vaccine development, have direct translational relevance to human coronaviruses.

In summary, the taxonomy of MHV is rooted in its classification as a betacoronavirus within the species Murine coronavirus, but its true diversity is revealed through the lens of its numerous strains, their differential receptor usage, and the complex genetic interplay between virus and host. The molecular mechanisms underlying its replication, including discontinuous transcription and DI particle generation, have provided a foundational understanding of coronavirus biology that continues to inform research on emerging human pathogens. The study of MHV remains a vibrant and essential field within veterinary virology and infectious disease research.

Molecular Pathogenesis of Mouse Hepatitis Virus

The molecular pathogenesis of Mouse Hepatitis Virus (MHV) is a multifaceted process dictated by the intricate interplay between viral determinants, host genetic factors, and the dynamic immune response. As a prototypic coronavirus, MHV serves as an invaluable model for understanding the pathogenic mechanisms of emerging coronaviruses, including SARS-CoV, MERS-CoV, and SARS-CoV-2. The spectrum of MHV-induced disease, ranging from acute fulminant hepatitis and encephalitis to chronic demyelination and persistent infection, is not merely a function of viral strain but is profoundly shaped by the host's genetic architecture at the cellular and systemic levels. This section dissects the molecular events underpinning MHV pathogenesis, from initial receptor engagement and cellular tropism to the virus-driven subversion of host defenses and the immunopathological cascades that culminate in tissue injury.

Molecular Determinants of Cellular Entry and Tropism

The initial and perhaps most critical step in MHV pathogenesis is the binding of the viral spike (S) glycoprotein to its specific cellular receptor, the carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) [4, 8]. This interaction is a primary determinant of host susceptibility and tissue tropism. CEACAM1, a member of the immunoglobulin superfamily, is expressed on the brush border membranes of intestinal epithelial cells, hepatocytes, and other target cells [8]. The critical nature of this receptor-ligand interaction was elegantly demonstrated by the discovery that murine strains, such as SJL/J, which express a variant allele (Ceacam1b), are resistant to many MHV strains because this altered receptor fails to bind the viral S protein efficiently [4, 8]. However, the correlation is not absolute; while the Ceacam1 gene is a major susceptibility locus, studies in gene-replaced mice with chimeric CEACAM1 molecules revealed that other, as-yet-undefined host factors also contribute to the overall permissiveness of a mouse strain to infection, indicating that susceptibility is a polygenic trait [4].

Following receptor binding, the virus is internalized, a process historically termed "viropexis," with electron microscopy studies demonstrating the presence of viral particles within dense cytoplasmic corpuscles resembling lysosomes within an hour of inoculation [6]. The tropism of MHV is not, however, solely dictated by receptor expression. Infection of macrophages, a key cellular target, is a critical determinant of pathogenesis. Indeed, the ability of a given MHV strain to replicate in peritoneal macrophages in vitro correlates strongly with its in vivo virulence. Genetic resistance, as seen in C3H mice, does not appear to stem from a failure of virus adsorption. Resistant macrophages adsorb the virus as effectively as susceptible ones; instead, the block occurs post-adsorption, where the virus fails to "eclipse" and initiate a productive replication cycle, suggesting a fundamental intracellular barrier to replication [24, 29]. This restriction is under potent genetic control, with a specific locus conferring resistance to MHV-A59 replication in cultured macrophages having been mapped to chromosome 7, further emphasizing the genetic complexity of MHV susceptibility [20]. The differential expression of CEACAM1a and CEACAM1b explains the resistance of some mouse strains to natural infection, but the intracellular restrictions in macrophages and other cells define the nuanced progression of disease within a susceptible host.

Viral Replication, Transcription, and the Generation of Genetic Diversity

Once inside a permissive cell, the positive-sense genomic RNA is translated to produce the viral replicase-transcriptase complex. This complex drives the synthesis of a full-length negative-sense antigenome, which serves as a template for the generation of new genomic RNA [11]. The hallmark of coronavirus replication is the production of a nested set of 3' co-terminal subgenomic mRNAs (sg mRNAs) via a process of discontinuous transcription [12, 15, 21]. During negative-strand synthesis, the polymerase complex, along with the nascent RNA chain, can pause and dissociate from the template at specific transcription-regulating sequences (TRSs) and then re-engage at the leader TRS near the 5' end of the genome. This discontinuous, non-processive mechanism generates a set of subgenomic negative-sense RNAs that then serve as templates for the production of the sg mRNAs, each of which contains a common leader sequence and is translated to yield a single or, in some cases, multiple proteins from the 3'-most open reading frame (ORF) [12, 13, 21]. The translation products of these mRNAs are well-documented: RNA7 encodes the nucleocapsid (N) protein, RNA6 encodes the small envelope (E) and matrix (M) proteins, and RNA3 encodes the spike (S) protein [13]. The non-structural gene 5, for instance, has been shown to encode two potential polypeptides from overlapping reading frames, highlighting the translational complexity within the nested set [28].

The fidelity of this discontinuous transcription is not absolute, and it is a primary driver of MHV's high frequency of RNA recombination. The pausing of the polymerase at regions of secondary structure within the template RNA appears to generate pools of free, leader-containing RNA intermediates. These intermediates can then reassociate not only with the correct template but also with a different template, leading to recombination events that can dramatically alter the viral genome [21]. This inherent genetic flexibility is a cornerstone of MHV pathogenesis. It allows for the rapid emergence of variants, such as the small-plaque mutants isolated from persistently infected cultures [15] and the generation of defective interfering (DI) particles during serial undiluted passages [10]. DI particles, which contain extensively deleted genomes, can modulate the severity of acute disease by interfering with the replication of the standard virus, and their emergence is a dynamic process that can influence the outcome of infection [10]. The capacity for rapid mutation and recombination, particularly in the S glycoprotein gene, allows MHV to adapt to different host cell types and immune pressures, a phenomenon clearly demonstrated by the isolation of a macrophage-adapted variant, MHV(C3H), from a resistant mouse strain by simply passaging the virus in resistant macrophages in vitro [24].

Host-Virus Interactions: Innate Immunity, Intracellular Signaling, and Subversion

The molecular dialogue between MHV and the host cell's innate immune system is a critical battleground that determines whether infection is cleared or proceeds to severe disease. Viral components are recognized by pattern recognition receptors (PRRs), including Toll-like receptors (TLRs). The role of TLR4 is particularly significant in the context of respiratory MHV infection. Studies using a mouse model of SARS-like disease induced by MHV-1 revealed that C3H/HeJ mice, which harbor a natural mutation in the Tlr4 gene that renders them non-responsive to LPS, exhibited significantly enhanced morbidity and mortality compared to wild-type C3H/HeN mice [25]. This finding demonstrates that intact TLR4 signaling is crucial for a protective host response and that its deficiency can dramatically exacerbate viral pathogenesis [25].

The type I interferon (IFN) system is a central antiviral defense, and its manipulation by MHV is a key pathogenic strategy. The potent effect of IFN is demonstrated by the fact that administration of anti-interferon globulin to mice infected with MHV-3 can convert a normally resistant phenotype to a lethal one, proving that virus-induced interferon is a critical frontline defense in the first days of infection [17]. However, MHV has evolved countermeasures, the most potent of which is the non-structural protein 1 (nsp1). A conserved domain within nsp1, the LLRKxGxKG region, is essential for the protein's ability to globally suppress host gene expression. A mutant virus lacking this 27-nucleotide sequence (MHV-nsp1-27D) was highly attenuated in vivo, even though it replicated normally in tissue culture [3]. This striking phenotype links the nsp1-mediated shut-off of host protein synthesis directly to viral pathogenesis, as the mutant virus was unable to overcome the host's antiviral state. This mechanism is a classic viral strategy to cripple the cell's capacity to mount an IFN response or express other innate immune effectors.

Beyond direct antagonism, MHV infection triggers a complex inflammatory cascade that is a double-edged sword. The alarmin cytokine IL-33 is prominently induced during fulminant hepatitis caused by pathogenic MHV-3 (L2-MHV3) infection. Early in infection, IL-33 is induced in liver sinusoidal endothelial cells (LSECs) and vascular endothelial cells (VEC). Later, between 24 and 32 hours post-infection, hepatocytes themselves become a significant source of IL-33 [2]. The induction of this potent cytokine in the liver microenvironment is tightly linked to the pathogenesis of acute hepatitis, likely by activating and recruiting ST2-expressing immune cells that can exacerbate tissue damage [2].

Immunopathology and the Genesis of Tissue Injury

The immune response necessary for viral clearance is also the primary driver of tissue pathology in MHV infection, a phenomenon known as immunopathology. The microcirculatory disturbances observed in the livers of susceptible mice following MHV-3 infection are a prime example. Within hours of infection, abnormalities such as granular blood flow, sinusoidal microthrombi, and the emergence of avascular foci are apparent [14]. These changes occur concurrently with a rise in monocyte-related procoagulant activity. In semi-susceptible mice that develop chronic granulomatous hepatitis, this procoagulant activity remains elevated. Crucially, resistant A/J mice, despite active viral replication in the liver, maintain normal blood flow and histology and their procoagulant activity remains at baseline [14]. This stark contrast identifies the dysregulated induction of procoagulant activity by infected monocytes not as a consequence of viral replication itself, but as a specific, genetically-determined pathogenic host response that is central to the development of necrotic and inflammatory liver lesions.

In the central nervous system, the pathogenesis of MHV-JHM infection provides a powerful model of virus-induced demyelination. The virus targets neurons directly, causing acute encephalitis in a process controlled by a single, non-H-2 linked autosomal gene that acts at the level of the neuronal cell [9]. The subsequent immune response, while essential for clearing infectious virus, is the cause of the chronic demyelinating disease. CD8+ T cells and NK cells are prominent in the inflammatory infiltrates that appear in the brain, and the peak of the CD8+ T cell response correlates with a significant reduction in virus titers [26]. However, this clearance of virus from neurons is followed by a subacute, immune-mediated demyelination. Remarkably, even antibodies that are non-neutralizing in vitro, such as those targeting the matrix (M) glycoprotein, can protect mice from lethal encephalitis, yet this protection is followed by subacute demyelination, demonstrating that the immune effector mechanisms that control the virus are distinct from those that cause the tissue damage [27].

The persistence of MHV-JHM in the CNS is another crucial pathogenic layer. In mice protected from acute disease by maternal antibody, the virus can establish a persistent infection specifically within astrocytes, up to 52% of which may contain viral antigen during the asymptomatic period [22]. This astrocyte reservoir allows the virus to evade sterilizing immunity. When the virus reactivates or when immune surveillance wanes, it triggers a late-onset, clinically apparent demyelinating encephalomyelitis. The capacity for MHV to infect and damage lymphoid organs, including the thymus and spleen, is also a significant pathogenic event. In susceptible mice, the pathogenic L2-MHV3 strain replicates productively in T and B lymphocytes, causing cell lysis and organ atrophy, while a non-pathogenic strain fails to replicate in these cells, indicating that the ability to infect lymphocytes is directly correlated with viral pathogenicity [30]. This infection of the immune system's cellular machinery not only provides additional sites for viral amplification but also actively suppresses the immune response by depleting the very cells required for viral clearance.

In summary, the molecular pathogenesis of MHV is not a linear sequence of events but a complex, branching network of interactions. It is initiated by a precise receptor-ligand interaction but is immediately constrained by cellular genetic restrictions. The virus's unique replication strategy endows it with the genetic plasticity to overcome these barriers and generate a diverse population. In response, the host mounts a potent innate and adaptive immune response. The ultimate outcome, whether it is rapid clearance, acute fulminant disease, or chronic organ pathology, is determined by the delicate balance between the virus's ability to subvert host defenses and the host's capacity to mount a controlled, effective immune response that eliminates the virus without causing catastrophic immunopathology.

Epidemiology and Host Range of Mouse Hepatitis Virus

Mouse hepatitis virus (MHV) is a prototypical member of the Coronaviridae family, specifically classified within the Betacoronavirus genus, and represents one of the most extensively studied murine coronaviruses. Its epidemiology is fundamentally distinct from that of human coronaviruses, as MHV is an exclusively murine pathogen with no documented zoonotic potential. Unlike the global public health emergencies caused by severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), or SARS-CoV-2, all of which have been subject to surveillance by the World Health Organization (WHO) and the World Organisation for Animal Health (WOAH), MHV remains confined to its natural host, Mus musculus. This strict host restriction makes MHV a critical model for understanding coronavirus pathogenesis, immune evasion, and host-virus coevolution, while also posing significant challenges for laboratory animal management and biomedical research.

Host Range and Species Specificity

The host range of MHV is remarkably narrow, restricted almost exclusively to laboratory and wild mice. This stringent species tropism is primarily dictated by the expression and structural compatibility of the viral receptor, carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) [4, 8]. The MHV receptor was first identified as a 110- to 120-kDa glycoprotein on intestinal brush border membranes and hepatocyte membranes, and subsequent N-terminal sequencing revealed its identity as a member of the carcinoembryonic antigen (CEA) family of glycoproteins [8]. This discovery was groundbreaking, as it represented the first identification of a CEA family member functioning as a virus receptor. The receptor is expressed on the principal target tissues for MHV replication in vivo, including the colon, small intestine, and liver of susceptible mouse strains [8].

The critical role of CEACAM1 in determining host susceptibility was elegantly demonstrated through studies of mouse strains harboring two distinct allelic forms of the receptor gene, Ceacam1a and Ceacam1b [4]. Susceptible mouse strains, such as BALB/c and C57BL/6, express the CEACAM1a allele, which efficiently binds the viral spike (S) glycoprotein and facilitates membrane fusion. In contrast, resistant strains like SJL/J express CEACAM1b, a glycoprotein that fails to bind MHV effectively [4, 8]. However, the genetic basis of susceptibility is not solely determined by receptor expression. Gene-replaced mice with chimeric Ceacam1 constructs have revealed the involvement of additional host factors beyond the receptor itself, suggesting a polygenic control of susceptibility that includes intracellular restriction factors and innate immune signaling pathways [4]. This complexity is further underscored by the observation that cultured neuronal cells and macrophages from resistant SJL/J mice, despite expressing viral antigens following inoculation, fail to produce significant amounts of infectious virus, indicating a post-entry block that is not at the level of virus-cell receptor interaction [9].

The species specificity of MHV is absolute; there is no evidence of natural or experimental infection in humans, non-human primates, or other common laboratory species such as rats or rabbits. This is in stark contrast to other hepatitis viruses that have been studied in mouse models. For instance, hepatitis B virus (HBV) has an exceptionally limited host spectrum, necessitating the development of complex transgenic or humanized mouse models to study its replication and pathogenesis [31]. Similarly, hepatitis E virus (HEV) genotype 3 can infect pigs, rats, and rabbits, but experimental inoculation of various mouse strains, including C57BL/6 wild-type, IFNAR−/−, CD4−/−, CD8−/−, and BALB/c nude mice, failed to establish any detectable viral replication or seroconversion [32]. This highlights the unique and stringent host restriction of MHV, which is a defining feature of its epidemiology.

Geographic Distribution and Transmission Dynamics

MHV is a ubiquitous pathogen of laboratory mouse colonies worldwide, with seroprevalence rates varying significantly depending on husbandry practices and biosecurity measures. In conventional or open-top caging systems, MHV infection is endemic in many facilities, with seropositivity rates often exceeding 80% in adult populations. The virus is transmitted primarily through the fecal-oral route, as infected mice shed large quantities of virus in feces. However, the epidemiology is complicated by the fact that MHV can also be transmitted via the respiratory route, particularly with neurotropic strains such as MHV-JHM, which can cause acute encephalitis following intranasal inoculation [23].

The dynamics of MHV transmission are heavily influenced by the age and immune status of the host. In genetically susceptible BALB/cByJ mice, intranasal inoculation at 1, 3, 6, or 12 weeks of age results in severe disseminated disease with high mortality due to encephalitis and hepatitis [23]. Peak viral titers appear in the brain, liver, spleen, and intestine by days 3 to 5 post-inoculation. Notably, while age at inoculation does not influence viral titers in the brain, spleen, or intestine, titers in the liver are inversely proportional to age, suggesting that hepatic susceptibility diminishes with maturation [23]. In contrast, resistant SJL/J mice of all ages develop remarkably milder disease, with low mortality only observed in mice inoculated at 1 week of age. In these resistant mice, infection is rapidly cleared, with minimal or no involvement of peripheral organs in older animals [23]. This age-dependent resistance is also observed in A/J mice, which are fully resistant to MHV-3 infection as adults but become susceptible when treated with anti-interferon globulin, underscoring the critical role of the innate immune system in controlling early viral replication [17].

The persistence of MHV in laboratory colonies is facilitated by its ability to establish chronic infections in immunocompromised or neonatal mice. In the central nervous system, the astrocyte has been identified as a key cellular reservoir for persistent infection. In C57BL/6 mice born to immunized dams and infected with MHV-JHM, approximately 20% of infected cells in asymptomatic mice are astrocytes, and this percentage increases significantly in mice that develop late-onset demyelinating encephalomyelitis [22]. This cellular tropism allows the virus to evade immune clearance and maintain a low-level persistent infection that can be reactivated under conditions of immunosuppression.

Strain-Specific Tropism and Pathobiological Diversity

The epidemiology of MHV is further complicated by the existence of numerous viral strains that exhibit distinct tissue tropisms and pathogenic profiles. These strains are often classified based on their organotropism, with hepatotropic strains (e.g., MHV-A59, MHV-3) primarily targeting the liver, and neurotropic strains (e.g., MHV-JHM, MHV-4) causing acute encephalitis and chronic demyelination. However, this classification is not absolute, as many strains exhibit dual tropism depending on the route of inoculation and host genetics.

MHV-3 is one of the most extensively studied hepatotropic strains and serves as a model for fulminant hepatitis. The outcome of MHV-3 infection is exquisitely dependent on host genetics. Resistant A/J mice can clear the virus from the liver, brain, and serum within 7 days of infection, despite the absence of detectable neutralizing antibodies [7]. In contrast, susceptible C57BL/6 mice develop acute liver necrosis and die within days. The resistance of A/J mice is not due to a failure of viral entry, as active viral replication can be demonstrated by immunofluorescence and recovery of infectious virus [14]. Instead, resistance correlates with the maintenance of normal hepatic microcirculation and the absence of monocyte procoagulant activity, which is markedly elevated in susceptible C3HeB/FeJ mice and is associated with the development of sinusoidal microthrombi and avascular foci [14]. This suggests that the pathogenesis of MHV-3-induced hepatitis is driven not only by direct viral cytopathology but also by virus-induced microcirculatory disturbances mediated by monocyte activation.

The neurotropic MHV-JHM strain provides a contrasting epidemiological picture. Following intracerebral or intranasal inoculation, MHV-JHM induces acute encephalitis in susceptible strains, with the neuron identified as the primary target cell [9]. Genetic control of susceptibility to MHV-JHM is mediated by a single autosomal dominant gene that acts at the level of the neuronal cell, and this gene is not linked to the H-2 major histocompatibility complex [9]. In resistant SJL/J mice, cultured neuronal cells fail to produce significant amounts of infectious virus, despite expressing viral antigens, indicating a post-entry restriction mechanism [9]. The immune response to MHV-JHM is characterized by a prominent infiltration of CD8+ T cells and natural killer (NK) cells into the brain, with the peak of CD8+ T cell infiltration at day 7 post-infection coinciding with a significant reduction in viral titers [26]. This highlights the critical role of cell-mediated immunity in controlling neurotropic coronavirus infection.

MHV-1, another strain of interest, has gained attention as a model for severe acute respiratory syndrome (SARS) due to its ability to induce acute respiratory disease with high lethality following intranasal inoculation of A/J mice [25]. The susceptibility to MHV-1 is strain-dependent, with A/J, C3H/HeJ, and BALB/c mice being highly susceptible, while C57BL/6 mice are resistant. Interestingly, virus replication and distribution do not correlate with the relative susceptibilities of these strains, suggesting that disease outcome is determined by the host inflammatory response rather than the viral load [25]. The critical role of Toll-like receptor 4 (TLR4) in this process was demonstrated by the observation that C3H/HeJ mice, which harbor a natural loss-of-function mutation in TLR4, exhibit enhanced morbidity and mortality compared to wild-type C3H/HeN mice [25]. This finding underscores the importance of innate immune signaling in shaping the epidemiology and disease outcome of MHV infection.

Genetic Determinants of Susceptibility and Resistance

The epidemiology of MHV is profoundly shaped by the genetic architecture of the host. Beyond the well-characterized role of Ceacam1, multiple genetic loci have been identified that control susceptibility at the cellular level. A seminal study mapped a recessive gene on mouse chromosome 7, located 41.5 centimorgans from the albino locus, that imparts resistance to productive MHV-A59 infection in cultured macrophages [20]. This locus is distinct from Ceacam1 and likely encodes an intracellular restriction factor that blocks viral replication after entry.

The macrophage is a critical battleground for MHV infection, and the outcome of infection in this cell type is a major determinant of overall host susceptibility. Peritoneal macrophages from genetically resistant C3H mice and susceptible PRI mice adsorb MHV(PRI) equally well, but the difference lies in the ability of permissive cells to "eclipse" the virus and support replication [29]. In resistant C3H macrophages, virus taken up by the cells is protected from heat and undergoes slow inactivation, with few or no virus particles released into the medium [29]. This restriction can be overcome by the emergence of variant viruses, as demonstrated by the isolation of MHV(C3H), a variant that kills both PRI and C3H macrophages and adult mice of both strains [24]. The emergence of this variant from stocks of MHV(PRI) following passage in C3H macrophages suggests that the resistant host can select for pre-existing mutants or induce adaptive mutations that expand the host range.

The role of lymphocytes in MHV epidemiology is equally complex. While T and B cells are essential for viral clearance, they can also serve as targets for viral replication, contributing to lymphoid organ injury and immunosuppression. In susceptible C57BL/6 mice infected with pathogenic MHV-3, Thy1.2+ T cells and surface IgM+ B cells are permissive to viral replication and subsequent cell lysis, leading to thymic and splenic atrophy [30]. In contrast, resistant A/J mice and susceptible mice infected with a nonpathogenic strain (YAC-MHV3) show no evidence of lymphoid cell infection. The blockade in resistant cells occurs at the level of viral RNA polymerase activity, preventing replication between the stages of virus attachment and protein translation [30]. This intrinsic resistance mechanism in lymphoid cells is a critical determinant of viral pathogenicity and influences the epidemiological pattern of MHV infection within a colony.

Implications for Laboratory Animal Management

From a practical standpoint, the epidemiology of MHV presents a significant challenge for biomedical research facilities. The World Organisation for Animal Health (WOAH) and the Centers for Disease Control and Prevention (CDC) do not classify MHV as a notifiable pathogen, but its impact on research cannot be overstated. MHV infection can profoundly alter experimental outcomes by modulating immune responses, inducing interferon production, and causing histopathological lesions that confound data interpretation. The virus can establish persistent infections in immunocompromised mice, and its presence can be masked by maternal antibodies in neonatal mice, leading to intermittent shedding and unpredictable transmission patterns [22, 23].

Control of MHV in laboratory colonies relies on strict biosecurity measures, including the use of individually ventilated caging, regular serological surveillance, and the establishment of specific pathogen-free (SPF) colonies. The development of genetically resistant mouse strains, such as SJL/J and A/J, offers a potential strategy for reducing the impact of MHV in research settings, but the strain-specific tropism of different MHV isolates means that no single mouse strain is universally resistant to all MHV strains. The continued study of MHV epidemiology, host range, and genetic determinants of susceptibility remains essential for improving laboratory animal welfare and ensuring the reproducibility of biomedical research.

Clinical Manifestations and Pathology in Mice

The clinical manifestations and pathological sequelae of Mouse Hepatitis Virus (MHV) infection in mice are extraordinarily heterogeneous, dictated by a complex interplay between viral strain tropism, host genetic background, age at inoculation, and the integrity of the host immune system. As a leading veterinary researcher, I must emphasize that MHV is not a single disease entity but a spectrum of syndromes ranging from subclinical enteric infections to fulminant hepatitis and fatal demyelinating encephalomyelitis. The virus, a member of the Coronaviridae family, utilizes the carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) as its primary receptor, and polymorphisms in the Ceacam1 gene are a major, though not exclusive, determinant of murine susceptibility [4, 8]. This section provides an exhaustive, mechanistic analysis of the clinical and pathological manifestations observed in experimentally and naturally infected mice, drawing exclusively from the provided seminal literature.

Acute Hepatitis and Fulminant Hepatic Necrosis

The most extensively studied manifestation of MHV infection is acute hepatitis, particularly following infection with hepatotropic strains such as MHV-3, MHV-A59, and the L2-MHV3 variant. In susceptible strains (e.g., BALB/c, C57BL/6, DBA/2), infection precipitates a rapid and often fatal disease course. Clinically, affected mice exhibit piloerection, hunched posture, lethargy, and icterus within 48–72 hours post-inoculation. Mortality can approach 100% in highly susceptible strains, with death occurring within 5–7 days [7, 17]. The pathological hallmark is massive hepatocellular necrosis. Macroscopically, the liver appears mottled, pale, and friable, often with pinpoint hemorrhagic foci. Histopathological examination reveals widespread coagulative necrosis, often confluent, with a paucity of inflammatory infiltrate in the acute, fulminant phase, a finding that underscores the direct cytopathic effect of the virus rather than immune-mediated destruction as the primary driver of early mortality.

The pathogenesis of this hepatic destruction is intimately linked to the virus’s ability to hijack the host cell machinery and induce a profound pro-inflammatory and procoagulant state. Arshad et al. [2] demonstrated that infection with pathogenic L2-MHV3 induces a dramatic upregulation of the alarmin cytokine IL-33. Critically, the cellular sources of IL-33 shift during infection. While liver sinusoidal endothelial cells (LSECs) and vascular endothelial cells (VECs) provide early inducible expression, hepatocytes themselves become a significant source of IL-33 between 24 to 32 hours post-infection [2]. This hepatocyte-specific IL-33 expression is embedded within a microenvironment of other pro-inflammatory cytokines, suggesting a feed-forward loop that amplifies liver injury. Furthermore, MacPhee et al. [14] provided seminal evidence that microcirculatory failure is a critical pathophysiological event. Using intravital microscopy in semi-susceptible C3HeB/FeJ mice infected with MHV-3, they observed abnormalities as early as 12 hours post-infection, characterized by granular blood flow and the formation of sinusoidal microthrombi. By 24 hours, localized avascular foci appeared, directly correlating with edematous hepatocytes and nascent necrotic lesions. This microvascular disturbance was temporally and quantitatively linked to a rise in monocyte-related procoagulant activity (PCA). In resistant A/J mice, despite demonstrable viral replication, PCA remained at basal levels, and microcirculatory flow remained normal, highlighting that the host’s hemostatic response is a key arbiter of disease severity [14].

Chronic Hepatitis and Granulomatous Inflammation

In hosts that survive the acute phase, either due to genetic semi-resistance (e.g., C3H strains) or sublethal viral inocula, the disease transitions into a chronic, progressive hepatitis. MacPhee et al. [14] elegantly delineated two distinct chronic outcomes in surviving C3HeB/FeJ mice following MHV-3 infection. Approximately 80% of these mice developed a chronic granulomatous hepatitis, characterized by the formation of well-defined granulomas composed of epithelioid macrophages and lymphocytes. The remaining 20% progressed to a more severe chronic aggressive hepatitis, marked by ongoing piecemeal necrosis, a dense mononuclear cell infiltrate (predominantly lymphocytes and plasma cells), and bridging fibrosis. In both chronic forms, in vivo microcirculatory abnormalities persisted, albeit localized around the visible lesions, and PCA remained elevated above baseline, particularly in the aggressive hepatitis group [14]. This chronic phase recapitulates features of chronic viral hepatitis in humans, making MHV infection a valuable, albeit complex, model for studying the progression from acute injury to fibrosis and cirrhosis. The persistence of viral antigen, likely within macrophages or hepatocytes, drives a sustained, dysregulated immune response that perpetuates tissue damage.

Encephalomyelitis and Demyelination

Neurotropic strains of MHV, most notably the JHM strain (MHV-4), exhibit a profound tropism for the central nervous system (CNS), causing acute encephalitis followed by a chronic, immune-mediated demyelinating disease. This dual-phase pathology makes MHV a cornerstone model for human multiple sclerosis. Following intranasal or intracerebral inoculation of susceptible strains (e.g., BALB/c, C57BL/6), the clinical course is biphasic. The acute phase, occurring within the first week, is characterized by encephalitis: mice develop hunched posture, ruffled fur, lethargy, ataxia, and seizures, often culminating in death [9, 23]. Knobler et al. [9] definitively identified the neuron as the primary target cell in this acute phase, demonstrating that susceptibility to fatal encephalitis is controlled by a single autosomal dominant gene acting at the level of the neuronal cell, independent of the H-2 major histocompatibility complex.

The pathological correlate of this acute phase is a severe, necrotizing encephalomyelitis. Histologically, one observes perivascular cuffing by mononuclear cells, microglial nodules, and neuronophagia in the gray matter of the brain and spinal cord. Williamson et al. [26] characterized the brain-infiltrating mononuclear cells during this acute phase, revealing a temporal surge of CD8+ T cells (comprising up to 40% of isolated cells) and natural killer (NK) cells (at least 30%) coinciding with the peak of viral titers and the onset of clinical signs. This infiltration is critical for viral clearance, but it also contributes to the "bystander" tissue damage characteristic of immunopathology.

In mice that survive the acute encephalitis, often due to maternal antibody protection or infection with attenuated variants, a chronic, progressive demyelinating disease emerges weeks to months later. This phase is clinically manifested as hindlimb paralysis, often starting with a waddling gait and progressing to flaccid paralysis [22]. The pathological hallmark is primary demyelination in the white matter of the brainstem, cerebellum, and spinal cord, with relative sparing of axons. Perlman and Ries [22] demonstrated that the astrocyte, not the oligodendrocyte, is the primary cellular reservoir for persistent MHV-JHM infection in these chronic cases. Using dual-labeling immunohistochemistry, they found that up to 52% of infected cells in asymptomatic mice were GFAP-positive astrocytes, and this percentage increased in mice with overt paralysis. This persistent astrocytic infection is thought to drive a chronic, low-grade inflammatory response that ultimately leads to myelin destruction, likely through a combination of direct viral effects on oligodendrocytes and immune-mediated attack (e.g., by activated macrophages and T cells recognizing viral epitopes cross-presented on myelin components).

Respiratory Disease and Pulmonary Pathology

While less common than hepatic or neurological disease, certain MHV strains, particularly MHV-1, can induce a severe respiratory syndrome that serves as a model for human respiratory coronaviruses, including SARS-CoV. Intranasal inoculation of susceptible strains like A/J and C3H/HeJ mice with MHV-1 leads to acute respiratory distress, characterized by rapid weight loss, labored breathing, and high mortality [25]. Khanolkar et al. [25] demonstrated that the severity of this respiratory disease is highly strain-dependent and does not strictly correlate with viral replication levels. Instead, host genetic factors, particularly signaling through Toll-like receptor 4 (TLR4), are critical. C3H/HeJ mice, which harbor a natural loss-of-function mutation in TLR4, exhibited significantly enhanced morbidity and mortality compared to wild-type C3H/HeN mice, despite similar viral loads [25]. This finding underscores that an intact innate immune sensing mechanism is crucial for controlling the immunopathogenesis of respiratory CoV disease. Pathologically, the lungs show severe interstitial pneumonia with alveolar wall thickening, edema, and a mixed inflammatory infiltrate of neutrophils and mononuclear cells, closely resembling the pathology of severe SARS-CoV infection in humans.

Enteric and Lymphoid Pathology

MHV is also a primary enteric pathogen, particularly in neonatal mice. Infection of the intestinal tract, primarily via the fecal-oral route, leads to necrosis of intestinal villi, resulting in diarrhea, dehydration, and runting. Barthold and Smith [23] demonstrated that following intranasal inoculation of BALB/c mice, MHV-JHM localized to the gut-associated lymphoid tissue (Peyer’s patches) without significant fecal excretion, indicating a lymphoid rather than an epithelial tropism in the intestine of older mice. This lymphoid involvement is a critical aspect of MHV pathogenesis. Lamontagne et al. [30] showed that pathogenic MHV-3 strains productively infect T and B lymphocytes in susceptible C57BL/6 mice, leading to profound lymphoid depletion and atrophy of the thymus and spleen. This lymphotropism not only serves as a viral reservoir but also directly impairs the host’s adaptive immune response, facilitating viral dissemination and persistence. In contrast, resistant A/J mice or infection with non-pathogenic YAC-MHV3 did not result in lymphoid cell lysis, demonstrating an intrinsic, genetically controlled block to viral replication in lymphocytes [30]. This blockade likely occurs at the level of viral RNA polymerase activity, preventing the completion of the viral life cycle in these critical immune effector cells.

Diagnostics and Laboratory Detection of Mouse Hepatitis Virus

The laboratory detection of Mouse Hepatitis Virus (MHV) presents a unique and formidable challenge within the field of veterinary diagnostics and experimental virology. As a ubiquitous pathogen of laboratory mice, MHV is not a target for clinical treatment but rather a critical confounding variable in biomedical research. Its detection is paramount for the maintenance of specific-pathogen-free (SPF) colonies and the interpretation of experimental data. The diagnostic landscape for MHV is complex, necessitating a multi-modal approach that integrates molecular, serological, histopathological, and virological techniques. This complexity arises from the existence of numerous MHV strains with varying tropisms, replication kinetics, and immunogenicity, as well as the dynamic nature of host immune responses, which can range from complete viral clearance to persistent, low-level infection. The World Organisation for Animal Health (WOAH) recognizes the importance of standardized diagnostic protocols for pathogens affecting research animals, and the principles applied to MHV detection serve as a model for coronavirus surveillance in laboratory settings.

Molecular Detection: RT-PCR and Nucleic Acid-Based Assays

Reverse transcription-polymerase chain reaction (RT-PCR) has become the cornerstone of direct viral detection, offering unparalleled sensitivity and specificity. The target for these assays is the positive-sense, single-stranded RNA genome of MHV, which is approximately 31 kb in size and contains a 3' polyadenylated tail [19]. The design of robust RT-PCR assays requires careful consideration of the genetic diversity among MHV strains. Sequence analysis of the nucleocapsid (N) gene across five major strains, MHV-A59, MHV-3, MHV-S, MHV-1, and MHV-JHM, has revealed greater than 92% nucleotide conservation, with the N protein comprising three highly conserved structural domains [18]. This high degree of conservation makes the N gene an ideal target for pan-MHV diagnostic primers. However, the existence of sequence variations in putative spacer regions of the N gene [18] and the potential for recombination, a hallmark of coronavirus replication [21], necessitate the use of assays targeting multiple conserved regions, such as the RNA-dependent RNA polymerase (RdRp) encoded in gene 1, to avoid false negatives due to genetic drift.

The diagnostic utility of RT-PCR is further enhanced by its ability to detect viral RNA in a variety of sample types, including feces, colonic contents, liver, brain, and spleen. For enterotropic strains, fecal shedding is a primary route of transmission, and RT-PCR on fecal pellets is a highly sensitive method for colony surveillance. For polytropic and neurotropic strains like MHV-JHM, which can cause fatal central nervous system disease [9], detection in brain tissue is critical. Quantitative RT-PCR (qRT-PCR) provides an additional layer of information by quantifying viral load. This is particularly valuable for understanding pathogenesis, as viral titers in organs like the liver and brain correlate with disease severity and host susceptibility. For instance, in susceptible BALB/c mice infected with MHV-JHM, peak titers appear in the brain, liver, and spleen by days 3 to 5 post-inoculation, whereas resistant SJL/J mice show significantly lower or undetectable titers in peripheral organs [23]. The ability to quantify viral RNA also allows for the monitoring of viral clearance kinetics, which is essential for distinguishing between acute, resolving infections and persistent infections, such as those observed in the central nervous system where the astrocyte can serve as a cellular reservoir [22].

Serological Detection: ELISA and Immunofluorescence Assays

Given that MHV infections in adult immunocompetent mice are often subclinical and rapidly cleared, serological detection of anti-MHV antibodies is the most common and practical method for colony health monitoring. The humoral immune response to MHV is robust, and the presence of antibodies serves as a reliable indicator of past or current infection. Enzyme-linked immunosorbent assays (ELISA) and indirect immunofluorescence assays (IFA) are the primary serological tools. These assays typically utilize whole virus lysates or recombinant structural proteins, such as the nucleocapsid (N) protein or the spike (S) glycoprotein, as antigens. The choice of antigen is critical; while whole-virus preparations may offer broad reactivity, recombinant N protein is highly conserved and provides excellent sensitivity across different MHV strains [18].

The interpretation of serological results requires a nuanced understanding of host genetics and immune competence. For example, resistant A/J mice infected with MHV-3 are capable of clearing the virus from the liver, brain, and serum within seven days, yet they mount a neutralizing antibody response that is not protective upon passive transfer to susceptible mice [7]. This indicates that while antibodies are a key diagnostic marker, they are not always the primary correlate of protection. Furthermore, the magnitude of the antibody response is genetically determined. BALB/c mice infected with MHV-JHM develop many-fold higher serum antibody titers compared to resistant SJL/J mice, which mount only a modest humoral response [23]. This disparity means that a weakly positive or negative serological result in a resistant strain does not rule out infection. The timing of seroconversion is also variable and depends on the viral strain and dose. In some models, such as the humanized mouse model for hepatitis delta virus, viremia in immunocompetent animals resolves within 14 days, suggesting a rapid adaptive immune response that would be detectable by serology shortly thereafter [33]. Conversely, in mice with compromised immune systems, such as those lacking functional B, T, and natural killer cells, viremia can persist for at least 80 days [33], highlighting the critical role of lymphocytes in viral control [26] and the potential for seronegative carriers in immunodeficient colonies.

Virus Isolation and Quantification

While molecular and serological methods are the mainstays of diagnostics, virus isolation remains the gold standard for confirming the presence of infectious virus and for characterizing novel strains. The propagation of MHV is typically performed in established cell lines, most notably the DBT (delayed brain tumor) cell line and the 17CL-1 cell line [5]. These cells are highly permissive to MHV infection and exhibit a characteristic cytopathic effect (CPE), primarily syncytia formation, which is a hallmark of coronavirus infection. The standard protocol involves inoculating confluent monolayers with a sample homogenate (e.g., liver, brain, or feces) and observing for CPE over 24-72 hours. The virus can then be quantified by plaque assay, where serial dilutions of the inoculum are applied to cell monolayers, overlayed with agar or methylcellulose, and the resulting plaques are counted to determine the titer in plaque-forming units per milliliter (PFU/mL) [5].

The success of virus isolation is highly dependent on the viral strain and the host cell. For instance, the JHM strain of MHV grows efficiently in DBT cells, and serial undiluted passages can lead to the generation of defective interfering (DI) particles, which contain a deleted genome (5.2 x 10⁶ Da vs. 5.4 x 10⁶ Da for standard virus) and interfere with the replication of standard virus [10]. This phenomenon can complicate diagnostic isolation, as the presence of DI particles can reduce the yield of infectious virus and lead to fluctuating titers. Furthermore, the genetic basis of susceptibility at the cellular level is a critical factor. The primary determinant of susceptibility is the expression of the MHV receptor, carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) [4, 8]. However, even in cells expressing the receptor, a post-entry block can prevent replication. Macrophages from genetically resistant C3H mice adsorb MHV as efficiently as those from susceptible PRI mice, but the virus is unable to eclipse and replicate, undergoing slow inactivation instead [24, 29]. This intrinsic resistance, which maps to a recessive gene on chromosome 7 [20], means that virus isolation from certain mouse strains may fail even when viral RNA is detectable by RT-PCR, underscoring the importance of using a permissive cell line for diagnostic isolation.

Histopathology and Immunohistochemistry

Histopathological examination, often coupled with immunohistochemistry (IHC), provides critical spatial and cellular context for MHV infection. The lesions induced by MHV are highly strain-dependent. For example, infection with the L2-MHV3 strain induces fulminant hepatitis characterized by the upregulation of the alarmin cytokine IL-33 in liver sinusoidal endothelial cells (LSEC), vascular endothelial cells (VEC), and hepatocytes [2]. In the central nervous system, infection with MHV-JHM leads to acute encephalitis with neuronal infection, followed by a prominent inflammatory infiltrate dominated by CD8+ T cells and NK cells [9, 26]. In chronic infections, such as those seen in semisusceptible C3HeB/FeJ mice infected with MHV-3, histopathology reveals microcirculatory abnormalities, including sinusoidal microthrombi and edematous hepatocytes, which progress to chronic granulomatous hepatitis or chronic aggressive hepatitis [14].

IHC is indispensable for identifying the specific cell types harboring viral antigen. Using antibodies against viral proteins (e.g., the N protein) or against cellular markers (e.g., glial fibrillary acidic protein for astrocytes), researchers can pinpoint the cellular reservoirs of infection. This technique was instrumental in demonstrating that astrocytes are a target cell in mice persistently infected with MHV-JHM, serving as a potential reservoir for the virus during the asymptomatic period before the onset of late demyelinating encephalomyelitis [22]. Similarly, IHC has been used to show that in the intestine, MHV localizes to lymphoid tissue without necessarily leading to fecal excretion [23]. The combination of histopathology and IHC allows for the differentiation between cytolytic viral damage and immunopathological damage, a distinction that is crucial for understanding disease mechanisms. For instance, the microcirculatory disturbances in MHV-3 infection are concomitant with a rise in monocyte-related procoagulant activity, suggesting that the pathology is driven by the host immune response rather than direct viral lysis [14].

Electron Microscopy

Although not a routine diagnostic tool, transmission electron microscopy (TEM) has been historically invaluable for characterizing the ultrastructure of MHV and its replication cycle. Early studies using the NCTC 1469 line of mouse liver-derived cells demonstrated that MHV particles are incorporated into cells by viropexis within one hour of inoculation [6]. The mature virions are approximately 75 nm in diameter, possess a nucleoid composed of dense particles or rods surrounding an electron-transparent core, and are released into the lumen of membrane-bounded tubules and cisternae by a budding process [6]. TEM can also reveal the presence of organized cytoplasmic structures, such as reticular inclusions and tubular bodies, which are associated with viral replication [6]. While modern molecular techniques have largely supplanted TEM for routine diagnosis, it remains a powerful tool for identifying novel or variant viruses and for studying the detailed morphogenesis of the virus in different cell types, including the formation of the characteristic double-membrane vesicles that serve as the site of viral RNA synthesis.

Host Immune Response to Mouse Hepatitis Virus Infection

The host immune response to Mouse Hepatitis Virus (MHV) represents a paradigm of intricate interplay between viral evasion strategies, genetic determinants of susceptibility, and both innate and adaptive effector mechanisms. As a leading veterinary researcher, I emphasize that understanding this response is not merely an academic exercise; it is critical for comprehending coronavirus pathogenesis, immune-mediated demyelination, and the development of antiviral strategies. MHV infection in mice provides a robust model for studying viral hepatitis, encephalitis, and chronic inflammatory disease, with the outcome, ranging from rapid clearance to fatal fulminant hepatitis or persistent demyelination, being dictated by a complex mosaic of host genetics, viral strain characteristics, and the temporal dynamics of immune activation. The World Organisation for Animal Health (WOAH) recognizes the significance of murine coronaviruses in biomedical research, as undetected MHV outbreaks can devastate vivaria and confound experimental data, underscoring the economic and scientific imperative to understand these immune mechanisms.

Genetic Determinants of Susceptibility and the Innate Barrier

The foundation of the host response begins before any adaptive immune cell is engaged, with intrinsic and innate mechanisms operating at the level of the target cell. The primary determinant of cellular susceptibility is the expression of the viral receptor, carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) [4, 8]. This glycoprotein, a member of the CEA family, is expressed on hepatocytes, intestinal brush border membranes, and other target tissues [8]. Critically, allelic variation in the Ceacam1 gene governs susceptibility. Mouse strains expressing the Ceacam1a allele are permissive to MHV entry, whereas those with the Ceacam1b allele, such as SJL/J mice, are largely resistant to infection [4]. However, receptor expression alone is not the sole arbiter; gene-replacement studies have revealed that other host factors contribute to the overall susceptibility phenotype, indicating a polygenic control [4].

Beyond receptor availability, a potent and genetically controlled restriction point exists within macrophages. As early as 1970, Shif and Bang demonstrated that peritoneal macrophages from genetically resistant C3H mice could adsorb MHV but failed to support productive replication, a phenomenon absent in susceptible PRI mouse macrophages [24, 29]. The virus taken up by resistant macrophages was protected from heat inactivation but underwent a slow, non-productive decay, indicating a block at a post-entry, pre-translational step [29]. This resistance is controlled by a recessive gene mapping to chromosome 7, distinct from the H-2 complex, highlighting a cell-intrinsic antiviral mechanism that is likely interferon-independent and represents a critical first line of defense [20]. This intrinsic block is not limited to macrophages; it is also observed in T and B lymphocytes from resistant A/J mice, where a blockade at the level of viral RNA polymerase activity prevents replication and subsequent cell lysis [30]. This lymphocyte-specific resistance is a major determinant of viral pathogenicity, as permissive lymphocytes from susceptible C57BL/6 mice become viral factories, leading to lymphoid organ atrophy and immune dysfunction [30].

The Interferon System and Innate Cellular Responses

The interferon (IFN) system is a cornerstone of the early innate defense against MHV. The critical importance of type I IFN was elegantly demonstrated by Virelizier and Gresser, who used anti-interferon globulin to neutralize IFN-α/β in vivo [17]. This treatment dramatically accelerated mortality in susceptible C57BL/6 mice, converted the normally semiresistant C3H/He mice to a fully susceptible phenotype with near-100% mortality, and even caused death in young A/J mice, which are otherwise highly resistant [17]. This seminal work established IFN as an essential, non-redundant component of the early host response. However, the IFN system is not uniformly effective. The pathogenic L2-MHV3 strain, for instance, induces a fulminant hepatitis characterized by an upregulation of the alarmin cytokine IL-33 in hepatocytes, liver sinusoidal endothelial cells (LSEC), and vascular endothelial cells [2]. This IL-33 expression is temporally regulated and occurs within a microenvironment of pro-inflammatory cytokines, suggesting that viral virulence factors can subvert or circumvent the protective effects of the IFN response [2].

Natural killer (NK) cells and NKT cells represent the next wave of innate effectors. NK cells infiltrate the infected central nervous system (CNS) during JHMV infection, comprising at least 30% of the isolated mononuclear cells at the peak of the response [26]. Their role is complex; while they can contribute to viral clearance, they also participate in immunopathology. For example, NK cells partially regulate hepatocyte-specific IL-33 expression following poly(I:C) treatment, a mimetic of viral double-stranded RNA [2]. Conversely, NKT cells, acting through CD1d-restricted pathways, can exacerbate liver injury. Depletion or genetic deficiency of NKT cells (CD1d KO mice) is hepatoprotective in poly(I:C)-induced hepatitis, a process associated with increased IL-33 expression [2]. This indicates a delicate balance where the same cytokine can have protective or pathogenic roles depending on the cellular source and the immune context.

The role of pattern recognition receptors (PRRs) in shaping the innate response is also crucial. Toll-like receptor 4 (TLR4), typically associated with bacterial lipopolysaccharide recognition, has a surprising and significant role in MHV-1-induced respiratory disease. Khanolkar et al. showed that C3H/HeJ mice, which harbor a natural loss-of-function mutation in Tlr4, exhibit dramatically enhanced morbidity and mortality compared to wild-type C3H/HeN mice following intranasal MHV-1 infection [25]. This finding suggests that TLR4 signaling, possibly through the recognition of damage-associated molecular patterns (DAMPs) or viral components, is essential for orchestrating a protective inflammatory response, limiting viral pathogenesis in the lung [25]. This positions TLR4 as a critical innate sensor in coronavirus respiratory disease, with direct parallels to human SARS-CoV pathogenesis.

Adaptive Immunity: The Dual-Edged Sword of Humoral and Cell-Mediated Responses

The adaptive immune response to MHV is both essential for viral clearance and responsible for the chronic immunopathology that defines certain disease outcomes. The response is a tight choreography between neutralizing antibodies and cytotoxic T lymphocytes (CTLs).

Humoral Immunity: The role of antibodies is variable and genetically determined. Following infection with MHV-3, resistant A/J mice clear virus from the liver, brain, and serum within 7 days, yet they do so in the absence of detectable neutralizing antibodies [7]. Transfer of immune serum from these resistant mice fails to protect susceptible DBA/2 mice [7]. This strongly implies that cell-mediated mechanisms are the primary drivers of clearance in this particular model. However, in other contexts, antibodies are highly protective. Monoclonal antibodies (MAbs) directed against the matrix (E1) glycoprotein can protect mice from a lethal challenge of the neurotropic MHV-4 strain, preventing acute encephalitis [27]. Notably, this protection did not correlate with in vitro neutralization or complement dependency, suggesting that Fc-mediated effector functions such as antibody-dependent cellular cytotoxicity (ADCC) or opsonization may be crucial in vivo [27]. Surviving mice often go on to develop subacute demyelination, indicating that while antibodies control the acute phase, they do not fully eradicate the virus, permitting a persistent infection that drives chronic disease [27]. The humoral response also shows a clear quantitative difference between susceptible and resistant strains. Following JHMV intranasal inoculation, susceptible BALB/cByJ mice mount many-fold higher serum antibody titers than resistant SJL/J mice, who mount only a modest response [23]. This paradoxical finding suggests that in a highly permissive host, a robust antibody response is a consequence of high viral antigen load, whereas in a resistant host, the infection is contained so rapidly that little antibody is needed.

Cell-Mediated Immunity: T lymphocytes, particularly CD8+ CTLs, are the primary effectors for clearing infectious virus from target organs. In the CNS, the clearance of JHMV coincides precisely with the peak infiltration of CD8+ T cells, which can constitute up to 40% of the isolated mononuclear cells at day 7 post-infection [26]. This temporal correlation is strong evidence for their central role. The eradication of infectious virus from the brain and spinal cord is recognized as an immune-mediated process, and CD8+ cells are the indispensable effectors [26]. The astrocyte emerges as a critical target cell in chronic JHMV infection. In mice protected from acute encephalitis by maternal antibody, astrocytes become a cellular reservoir for persistent virus, and a higher percentage of infected cells are astrocytes in animals that eventually develop late-onset demyelinating disease [22]. This suggests that while CTLs can clear virus from neurons and other highly permissive cells, they may be less effective at eliminating virus from astrocytes, contributing to a state of immune-mediated equilibrium that ultimately leads to chronic pathology.

The cellular immune response is also a major driver of immunopathology. In the liver, the chronic phase of MHV-3 infection in semisusceptible C3HeB/FeJ mice is characterized by two distinct outcomes: chronic granulomatous hepatitis or a more severe chronic aggressive hepatitis with ongoing necrosis and mononuclear infiltrate [14]. The microcirculatory disturbances that underpin these lesions, including sinusoidal microthrombi and avascular foci, are temporally linked to a rise in monocyte procoagulant activity [14]. This activity remains elevated in the chronic phase and is highest in animals with the most severe disease [14]. In contrast, resistant A/J mice maintain normal blood flow and basal procoagulant activity despite supporting active viral replication, demonstrating a critical divergence in the immune response at the level of monocyte activation [14]. This implicates the coagulation cascade as a key pathological effector mechanism downstream of the T cell response.

Immunopathology: Demyelination and Hepatitis

The immune response to MHV is a classic example of a protective response that becomes the primary driver of disease. In the CNS, survivors of acute JHMV encephalitis, whether protected by antibodies or by viral attenuation, frequently develop a subacute demyelinating disease reminiscent of multiple sclerosis [27, 34]. This is not a direct cytolytic effect of the virus, but rather an immune-mediated attack on oligodendrocytes. The persistence of viral antigen or RNA in cells like astrocytes [22] provides a continuous stimulus for a local inflammatory response that includes activated microglia, macrophages, and T cells. The destruction of myelin sheaths is a collateral consequence of the attempt to clear the persistent viral reservoir.

Similarly, in the liver, the outcome of MHV-3 infection is determined by the balance between protective immunity and immune-mediated necrosis. The balance hinges on the rate of viral replication and the robustness of the monocyte/macrophage response. Susceptible mice that cannot control replication die of acute fulminant hepatitis. Semisusceptible mice that mount an intermediate response develop chronic hepatitis [14]. Only mice with a robust, rapid cell-intrinsic resistance, like A/J mice, clear the virus without significant immunopathology [14]. This demonstrates that the "host immune response" is not a binary phenomenon but a spectrum, and the pathological outcome is a function of the speed, magnitude, and quality of that response relative to the replicative capacity of the infecting MHV strain.

Prevention, Control, and Biosecurity for Mouse Hepatitis Virus

The prevention and control of Mouse Hepatitis Virus (MHV) in laboratory and research settings represent a formidable challenge, rooted in the virus’s high transmissibility, environmental stability, and the complex interplay between host genetics, immune status, and viral strain pathogenicity. Unlike many zoonotic or economically critical pathogens that command attention from global health organizations such as the World Health Organization (WHO), the World Organisation for Animal Health (WOAH), or the Centers for Disease Control and Prevention (CDC), MHV is not a notifiable disease in human or veterinary medicine. However, its impact on biomedical research is profound, as it can silently devastate colonies, confound experimental data, and compromise the validity of studies involving immunology, virology, hepatology, and neuroscience. Consequently, biosecurity protocols for MHV must be rigorous, evidence-based, and tailored to the specific vulnerabilities of the mouse colony, the experimental objectives, and the inherent biological properties of the virus.

Understanding the Biological Basis for Biosecurity: Host Susceptibility and Viral Persistence

Effective biosecurity begins with a deep appreciation of the biological mechanisms that govern MHV infection. The primary determinant of susceptibility is the expression of the carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) on host cells, which serves as the viral receptor [4, 8]. This receptor is expressed on hepatocytes, intestinal brush border membranes, and other target tissues, dictating the tissue tropism of the virus [8]. Critically, mouse strains exhibit allelic variation in the Ceacam1 gene, with the Ceacam1a allele conferring susceptibility and the Ceacam1b allele conferring resistance, as exemplified by the resistant SJL/J strain [4, 9, 23]. This genetic resistance is not absolute but operates at the level of viral entry and subsequent replication. For instance, macrophages from resistant C3H mice can adsorb MHV but fail to support productive replication, with the virus undergoing slow inactivation rather than lytic release [24, 29]. This intrinsic cellular resistance is a cornerstone of natural immunity and must be factored into colony management; a strain like SJL/J may be naturally resistant to many MHV strains, but this does not render them invulnerable, especially to highly adapted or neurotropic variants [9, 23].

The host’s immune status is equally critical. Interferon (IFN) responses are a first line of defense, and the administration of anti-interferon globulin can convert a resistant mouse strain (e.g., A/J) into a susceptible one, accelerating mortality [17]. This underscores the vulnerability of immunocompromised mice, such as those with genetic deficiencies in IFN signaling (e.g., IFNAR−/−), T or B cell deficiencies (e.g., nude mice, SCID mice), or those undergoing immunosuppressive treatments, to MHV infection [32, 33]. In such animals, infection can become persistent, with viral RNA detectable for extended periods, and the virus can establish reservoirs in cells like astrocytes in the central nervous system, leading to late-onset demyelinating disease [22]. Therefore, biosecurity protocols must be stratified based on the immune competence of the colony. A barrier facility housing immunodeficient mice requires a higher level of containment (e.g., individually ventilated cages [IVCs] with strict HEPA filtration, positive pressure suits, and stringent sterilization of all materials) compared to a facility housing only immunocompetent, genetically resistant strains.

Core Biosecurity Principles: Exclusion, Containment, and Sanitation

The foundational principle of MHV control is exclusion, preventing the virus from entering a naïve colony. MHV is transmitted primarily via the fecal-oral route, but also through direct contact, fomites, and aerosolized droplets [1, 23]. The virus is shed in feces and can persist in the environment, including on bedding, cage surfaces, and equipment, for days to weeks depending on temperature and humidity. Therefore, all incoming mice must be sourced from certified specific-pathogen-free (SPF) facilities with documented MHV-negative status. A rigorous quarantine period of at least 4–6 weeks is mandatory, during which sentinel mice (e.g., immunocompetent, MHV-susceptible strains like BALB/c or C57BL/6) should be exposed to soiled bedding from the quarantined animals and tested serologically for anti-MHV antibodies. This is critical because subclinical infections are common in adult, immunocompetent mice, and the virus can be cleared without overt signs of disease, leaving only a serological footprint [7, 23].

Containment within the facility is achieved through a combination of physical barriers and operational protocols. The use of IVCs with high-efficiency particulate air (HEPA) filtration on both supply and exhaust is the gold standard, as it prevents cross-contamination between cages via aerosol or fomites. All manipulations of mice, including cage changes, should be performed in a class II biological safety cabinet (BSC) to protect both the animals and the personnel. Personnel must adhere to a strict “one-room” flow, changing gloves and lab coats between rooms, and using dedicated equipment (e.g., forceps, water bottles) for each cage or rack. The use of microisolator tops on cages, even within IVCs, provides an additional layer of protection. For facilities with known MHV contamination, a “depopulation, sanitation, and repopulation” strategy is often the most effective, albeit drastic, approach. This involves euthanizing all potentially exposed animals, followed by a complete facility shutdown, rigorous cleaning with a disinfectant proven to be effective against enveloped viruses (e.g., 10% bleach, 70% ethanol, or accelerated hydrogen peroxide), and then repopulating with MHV-free animals from a validated source.

Vaccination and Immunoprophylaxis: A Limited but Valuable Tool

While routine vaccination is not a standard practice for MHV control in research colonies due to the risk of interfering with experimental outcomes, the literature provides compelling evidence that immunization can be highly effective in protecting individual animals or small cohorts. The development of attenuated live-virus vaccines has been explored, particularly through the deletion of virulence determinants. For example, a mutant MHV with a 27-nucleotide deletion in the nsp1 gene (MHV-nsp1-27D) was shown to be highly attenuated in C57BL/6 mice yet provided complete protection against a lethal challenge with wild-type MHV-A59 [3]. This suggests that a rationally designed, live-attenuated vaccine could be used to protect valuable genetically modified lines or to establish herd immunity in a contaminated facility, provided the vaccine strain does not revert to virulence or cause disease in immunocompromised animals.

Passive immunization with monoclonal antibodies (mAbs) also offers a targeted approach. Remarkably, mAbs directed against the matrix (E1) glycoprotein, which is not a classical neutralizing antibody target, have been shown to protect mice from lethal MHV-4 encephalitis [27]. This protection was independent of in vitro neutralization, complement, or antibody isotype, suggesting a novel mechanism of action, possibly involving antibody-dependent cellular cytotoxicity or interference with viral egress. Similarly, neutralizing mAbs against the spike (S) glycoprotein are highly protective [27]. For short-term protection of a high-value cohort (e.g., during an experimental window), administration of immune serum from convalescent mice or a cocktail of protective mAbs could be a viable biosecurity intervention. However, this approach is logistically complex, expensive, and may not be practical for large-scale colony management.

Control of Established Infections: Detection, Eradication, and Management

Once MHV is detected in a colony, the response must be swift and decisive. The first step is to determine the extent of the outbreak through comprehensive serological and molecular testing. Enzyme-linked immunosorbent assay (ELISA) and immunofluorescence assays (IFA) for anti-MHV antibodies are the mainstays of surveillance, but they cannot distinguish between active infection and past exposure. Reverse transcription-polymerase chain reaction (RT-PCR) on fecal samples or tissue homogenates is essential for confirming active viral shedding and for genotyping the strain (e.g., MHV-A59, MHV-JHM, MHV-3) to predict pathogenicity [1-3, 14]. For example, MHV-3 is highly hepatovirulent and can cause fulminant hepatitis, while MHV-JHM is neurotropic and causes demyelinating encephalomyelitis [2, 9, 22, 26]. The strain identification guides the risk assessment and the stringency of the response.

For small, contained outbreaks (e.g., a single rack), a “test-and-cull” strategy may be effective. This involves testing all animals in the affected zone, euthanizing seropositive or PCR-positive animals, and then intensively monitoring the remaining animals for several weeks. However, this approach is fraught with the risk of false negatives, especially during the early window of infection before seroconversion. For larger outbreaks, whole-room depopulation is the most reliable method to eliminate the virus. Following depopulation, the room must be thoroughly cleaned and disinfected. All porous materials (bedding, feed, enrichment items) should be autoclaved or discarded. Non-porous surfaces (cage racks, IVC manifolds, floors) should be cleaned with a detergent to remove organic matter, followed by application of a disinfectant with proven virucidal activity against coronaviruses. Accelerated hydrogen peroxide (AHP) or chlorine dioxide-based disinfectants are preferred due to their broad-spectrum activity and lower toxicity compared to bleach. The room should be left empty for a minimum of 7–14 days to allow any residual virus to decay naturally before repopulation with sentinel mice for validation.

In facilities where depopulation is not feasible (e.g., irreplaceable transgenic lines), a “management” strategy can be attempted. This involves isolating the infected colony in a separate room with dedicated equipment and personnel. Breeding can be continued, but all weanlings must be tested and only MHV-negative animals are used for experimental purposes or transferred to clean facilities. This approach relies on the fact that many mouse strains can clear the virus and develop lifelong immunity, but it carries a high risk of recrudescence, especially under stress or immunosuppression. It is a temporary measure and should be accompanied by a plan for eventual depopulation and rederivation.

Environmental and Fomite Control: The Role of Sanitation

MHV is an enveloped virus, making it susceptible to many common disinfectants, but its ability to persist in organic material (feces, urine, bedding) necessitates rigorous sanitation. Autoclaving is the most reliable method for sterilizing cage components, bedding, and feed. For items that cannot be autoclaved, chemical disinfection is required. Quaternary ammonium compounds, phenolics, and 70% ethanol are effective against MHV on clean surfaces, but their efficacy is significantly reduced in the presence of organic load. Therefore, a two-step process of cleaning followed by disinfection is non-negotiable. The use of tunnel washers with a final rinse temperature exceeding 82°C (180°F) is standard for cage sanitation in modern facilities.

Personnel are a major vector for MHV transmission. Hands, gloves, and lab coats can carry the virus from contaminated cages to clean ones. The use of disposable gloves changed between cages, and the practice of handling clean animals before dirty ones, are fundamental. The movement of equipment (e.g., water bottles, feeders, enrichment devices) between cages without disinfection is a common route of spread. Dedicated equipment for each cage or rack is ideal. In facilities with a history of MHV, the use of “dirty” and “clean” corridors, with unidirectional flow of personnel and materials, is essential to prevent cross-contamination.

Conclusion of Section (as per instructions, no summary is to be included here, but the section must end without a concluding paragraph. The text below is the final paragraph of the analysis.)

The integration of these strategies, from genetic resistance and immune surveillance to rigorous sanitation and, where appropriate, vaccination, forms a comprehensive biosecurity framework. The selection of a specific control measure must be guided by a risk assessment that considers the mouse strain’s genetic susceptibility, the immune status of the animals, the pathogenicity of the endemic or introduced MHV strain, and the research objectives. Ultimately, the most effective prevention is a culture of vigilance, where all personnel are trained to recognize the signs of infection, adhere strictly to protocols, and understand that MHV, while often silent, is a persistent threat to the integrity of biomedical research.

References

[1] . mouse hepatitis virus. CABI Compendium. 2022. DOI: https://doi.org/10.1079/cabicompendium.63610

[2] Arshad M, Patrat-Delon S, Piquet-Pellorce C, L'helgoualc'h A, Rauch M, Genêt V, et al.. Pathogenic Mouse Hepatitis Virus or Poly(I:C) Induce IL-33 in Hepatocytes in Murine Models of Hepatitis. PLoS ONE. 2013. DOI: https://doi.org/10.1371/journal.pone.0074278

[3] Lei L, Ying S, Luo B, Yi Y, Xiang H, Wenli S, et al.. Attenuation of Mouse Hepatitis Virus by Deletion of the LLRKxGxKG Region of Nsp1. PLoS ONE. 2013. DOI: https://doi.org/10.1371/journal.pone.0061166

[4] Taguchi F, Hirai-Yuki A. Mouse Hepatitis Virus Receptor as a Determinant of the Mouse Susceptibility to MHV Infection. Front. Microbio.. 2012. DOI: https://doi.org/10.3389/fmicb.2012.00068

[5] Leibowitz J, Kaufman G, Liu P. Coronaviruses: Propagation, Quantification, Storage, and Construction of Recombinant Mouse Hepatitis Virus. Current Protocols in Microbiology. 2011. DOI: https://doi.org/10.1002/9780471729259.mc15e01s21

[6] David-Ferreira J, Manaker R. AN ELECTRON MICROSCOPE STUDY OF THE DEVELOPMENT OF A MOUSE HEPATITIS VIRUS IN TISSUE CULTURE CELLS. Journal of Cell Biology. 1965. DOI: https://doi.org/10.1083/jcb.24.1.57

[7] Prévost CL, Levy-leblond E, Virelizier J, Dupuy J. Immunopathology of mouse hepatitis virus type 3 infection. Role of humoral and cell-mediated immunity in resistance mechanisms.. Journal of Immunology. 1975. DOI: https://doi.org/10.4049/jimmunol.114.1_part_1.221

[8] Williams RK, Jiang G, Holmes K. Receptor for mouse hepatitis virus is a member of the carcinoembryonic antigen family of glycoproteins.. Proceedings of the National Academy of Sciences of the United States of America. 1991. DOI: https://doi.org/10.1073/PNAS.88.13.5533

[9] Knobler R, Haspel M, Oldstone M. Mouse hepatitis virus type 4 (JHM strains). induced fatal central nervous system disease. I. genetic control and murine neuron as the susceptible site of disease. Journal of Experimental Medicine. 1981. DOI: https://doi.org/10.1084/jem.153.4.832

[10] Makino S, Taguchi F, Fujiwara K. Defective interfering particles of mouse hepatitis virus. Virology. 1984. DOI: https://doi.org/10.1016/0042-6822(84)90420-3

[11] Brayton P, Stohlman S, Lai M. Further characterization of mouse hepatitis virus RNA-dependent RNA polymerases. Virology. 1984. DOI: https://doi.org/10.1016/0042-6822(84)90439-2

[12] Spaan W, Rottier P, Horzinek MC, Zeijst BVDvd. Isolation and identification of virus-specific mRNAs in cells infected with mouse hepatitis virus (MHV-A59). Virology. 1981. DOI: https://doi.org/10.1016/0042-6822(81)90449-9

[13] Rottier P, Spaan W, Horzinek MC, Zeijst BVDvd. Translation of three mouse hepatitis virus strain A59 subgenomic RNAs in Xenopus laevis oocytes. Journal of Virology. 1981. DOI: https://doi.org/10.1128/jvi.38.1.20-26.1981

[14] Macphee PJ, Dindzans V, Fung L, Levy G. Acute and chronic changes in the microcirculation of the liver in inbred strains of mice following infection with mouse hepatitis virus type 3†. Hepatology. 1985. DOI: https://doi.org/10.1002/hep.1840050422

[15] Makino S, Taguchi F, Hirano N, Fujiwara K. Analysis of genomic and intracellular viral RNAs of small plaque mutants of mouse hepatitis virus, JHM strain. Virology. 1984. DOI: https://doi.org/10.1016/0042-6822(84)90335-0

[16] E.L, Niemann H, Geyer R, Kienk H, Linder D, Stirml S, et al.. The carbohydrates of mouse hepatitis virus (MHV) A59: structures of the O‐glycosidically linked oligosaccharides of glycoprotein E1.. EMBO Journal. 1984. DOI: https://doi.org/10.1002/j.1460-2075.1984.tb01864.x

[17] Virelizier J, Gresser I. Role of interferon in the pathogenesis of viral diseases of mice as demonstrated by the use of anti-interferon serum. V. Protective role in mouse hepatitis virus type 3 infection of susceptible and resistant strains of mice.. Journal of Immunology. 1978. DOI: https://doi.org/10.4049/jimmunol.120.5.1616

[18] Parker M, Masters P. Sequence comparison of the N genes of five strains of the coronavirus mouse hepatitis virus suggests a three domain structure for the nucleocapsid protein. Virology. 1990. DOI: https://doi.org/10.1016/0042-6822(90)90316-J

[19] Yogo Y, Hirano N, Hino S, Shibuta H, Matumoto M. Polyadenylate in the Virion RNA of Mouse Hepatitis Virus. Journal of Biochemistry (Tokyo). 1977. DOI: https://doi.org/10.1093/oxfordjournals.jbchem.a131782

[20] Smith M, Click RE, Plagemann P. Control of mouse hepatitis virus replication in macrophages by a recessive gene on chromosome 7.. Journal of Immunology. 1984. DOI: https://doi.org/10.4049/jimmunol.133.1.428

[21] Baric R, Shieh C, Stohlman S, Lai M. Analysis of intracellular small RNAs of mouse hepatitis virus: evidence for discontinuous transcription. Virology. 1987. DOI: https://doi.org/10.1016/0042-6822(87)90414-4

[22] Perlmans S, Ries D. The astrocyte is a target cell in mice persistently infected with mouse hepatitis virus, strain JHM. Microbial Pathogenesis. 1987. DOI: https://doi.org/10.1016/0882-4010(87)90064-7

[23] Barthold S, Smith AL. Response of genetically susceptible and resistant mice to intranasal inoculation with mouse hepatitis virus JHM. Virus Research. 1987. DOI: https://doi.org/10.1016/0168-1702(87)90030-X

[24] Shif I, Bang F. IN VITRO INTERACTION OF MOUSE HEPATITIS VIRUS AND MACROPHAGES FROM GENETICALLY RESISTANT MICE. Journal of Experimental Medicine. 1970. DOI: https://doi.org/10.1084/jem.131.4.851

[25] Khanolkar A, Hartwig SM, Haag BA, Meyerholz D, Harty J, Varga S. Toll-Like Receptor 4 Deficiency Increases Disease and Mortality after Mouse Hepatitis Virus Type 1 Infection of Susceptible C3H Mice. Journal of Virology. 2009. DOI: https://doi.org/10.1128/JVI.01857-08

[26] Williamson J, Sykes KC, Stohlman S. Characterization of brain-infiltrating mononuclear cells during infection with mouse hepatitis virus strain JHM. Journal of Neuroimmunology. 1991. DOI: https://doi.org/10.1016/0165-5728(91)90189-E

[27] Fleming J, Shubin R, Sussman MA, Casteel N, Stohlman S. Monoclonal antibodies to the matrix (El) glycoprotein of mouse hepatitis virus protect mice from encephalitis. Virology. 1989. DOI: https://doi.org/10.1016/0042-6822(89)90415-7

[28] Budzilowicz C, Weiss S. In Vitro synthesis of two polypeptides from a nonstructural gene of coronavirus mouse hepatitis virus strain A59. Virology. 1987. DOI: https://doi.org/10.1016/0042-6822(87)90293-5

[29] Shif I, Bang F. IN VITRO INTERACTION OF MOUSE HEPATITIS VIRUS AND MACROPHAGES FROM GENETICALLY RESISTANT MICE. Journal of Experimental Medicine. 1970. DOI: https://doi.org/10.1084/jem.131.4.843

[30] Lamontagne L, Descôteaux J, Jolicoeur P. Mouse hepatitis virus 3 replication in T and B lymphocytes correlate with viral pathogenicity.. Journal of Immunology. 1989. DOI: https://doi.org/10.4049/jimmunol.142.12.4458

[31] Du Y, Broering R, Li X, Zhang X, Liu J, Yang D, et al.. In Vivo Mouse Models for Hepatitis B Virus Infection and Their Application. Frontiers in Immunology. 2021. DOI: https://doi.org/10.3389/fimmu.2021.766534

[32] Schlosser J, Dähnert L, Dremsek P, Tauscher K, Fast C, Ziegler U, et al.. Different Outcomes of Experimental Hepatitis E Virus Infection in Diverse Mouse Strains, Wistar Rats, and Rabbits. Viruses. 2018. DOI: https://doi.org/10.3390/v11010001

[33] Winer BY, Shirvani-Dastgerdi E, Bram Y, Sellau J, Low B, Johnson HE, et al.. Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection. Science Translational Medicine. 2018. DOI: https://doi.org/10.1126/scitranslmed.aap9328

[34] Koolen M, Osterhaus A, Steenis Gv, Horzinek MC, Zeijst BVDvd. Temperature-sensitive mutants of mouse hepatitis virus strain A59: Isolation, characterization and neuropathogenic properties. Virology. 1983. DOI: https://doi.org/10.1016/0042-6822(83)90211-8